Antibody molecules which bind CD22
The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
1. An antibody molecule comprising a binding domain specific to CD22, wherein the binding domain comprises a heavy chain variable domain (VH) comprising CDR H1, CDR H2, and CDR H3 and a light chain variable domain (VL) comprising CDR L1, CDR L2, and CDR L3, wherein
CDR H1 is SEQ ID NO: 38 or 39;
CDR H2 is SEQ ID NO: 54, 55, 56, 57, 58, or 59;
CDR H3 is SEQ ID NO: 68;
CDR L1 is SEQ ID NO: 74;
CDR L2 is SEQ ID NO: 80; and
CDR L3 is SEQ ID NO: 101.
2. The antibody molecule according to claim 1 , wherein VH and VL are humanised.
3. The antibody molecule according to claim 2 , wherein the VH comprises a human framework region wherein at least one position in the heavy chain human framework is selected from the group consisting of position 48 is serine, position 49 is glycine, position 71 is asparagine, position 73 is serine, position 76 is threonine, and position 78 is valine, and/or the VL comprises a human framework region wherein at least one position in the light chain human framework is selected from the group consisting of position 3 is valine and position 71 is tyrosine, numbering according to Kabat.
4. The antibody molecule according to claim 1 , comprising a VH comprising SEQ ID NO: 154.
5. The antibody molecule according to claim 1 , comprising a VL comprising SEQ ID NO:153.
6. A composition comprising one or more antibody molecules according to claim 1 .
7. An antibody molecule comprising a VH comprising SEQ ID NO: 154 and a VL comprising SEQ ID NO:153.
8. A nucleotide encoding an antibody molecule, wherein the antibody comprises a binding domain specific to CD22, wherein the binding domain comprises a heavy chain variable domain (VH) comprising CDR H1, CDR H2, and CDR H3 and a light chain variable domain (VL) comprising CDR L1, CDR L2, and CDR L3 wherein
CDR H1 is SEQ ID NO: 38 or 39;
CDR H2 is SEQ ID NO: 54, 55, 56, 57, 58, or 59;
CDR H3 is SEQ ID NO: 68;
CDR L1 is SEQ ID NO: 74;
CDR L2 is SEQ ID NO: 80; and
CDR L3 is SEQ ID NO: 101.
9. The nucleotide of claim 8 , wherein the VH and VL are humanised.
10. The nucleotide of claim 8 , wherein the antibody comprises a VH comprising SEQ ID NO: 154.
11. The nucleotide of claim 8 , wherein the antibody comprises a VL comprising SEQ ID NO:153.
12. The nucleotide of claim 8 , wherein the antibody molecule comprises a VH comprising SEQ ID NO: 154 and a VL comprising SEQ ID NO:153.
13. A vector comprising the nucleotide of claim 8 .
14. The vector of claim 13 , wherein the vector is a plasmid or a viral vector.
15. The vector of claim 13 , wherein the vector is capable of autonomous replication in a host cell.
16. The vector of claim 13 , wherein the vector is a bacterial vector or an episomal mammalian vector.
17. The vector of claim 13 , wherein the vector is capable of being integrated into the genome of a host cell.
18. A host cell comprising the nucleotide of claim 8 .
19. A host cell comprising the vector of claim 13 .
20. The host cell of claim 13 , wherein the host cell is a bacterial cell.